U.S. FDA designates Hanmi Pharm’s LAPSGlucagon Analog as orphan drug
LAPSGlucagon Analog(HM15136) that Hanmi Pharm is developing as a congenital hyperinsulinemia treatment has been recognized as an orphan drug from the U.S. FDA on the 1st.
The Orphan Drug Designation program by the FDA is a system to support for smooth development and approval process for insurab...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
